Cadrenal Therapeutics, Inc. reported its full year results for the period ended December 31, 2024, on March 13, 2025. The company also provided a business update and highlighted its path forward for the clinical advancement of tecarfarin.
As a clinical-stage biopharmaceutical company, Cadrenal Therapeutics is focused on the development of tecarfarin, a novel oral vitamin K antagonist. The company emphasized its readiness to advance tecarfarin into Phase 3 clinical trials.
The update underscored the company's ongoing efforts to develop tecarfarin as a superior and safer chronic anticoagulant. This includes targeting warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.